Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review
A 72-year-old female and a 57-year-old male with chronic hepatitis C were treated with a combination therapy of pegylated interferon (PEG-IFN)-α 2a (180 µg s.c. once a week) and ribavirin (1,000 mg orally daily). This resulted in the destruction of melanocytes at the injection site in both patients....
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2010-08-01
|
| Series: | Case Reports in Dermatology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/320207 |
| _version_ | 1818164142321696768 |
|---|---|
| author | V. Arya M. Bansal L. Girard S. Arya A. Valluri |
| author_facet | V. Arya M. Bansal L. Girard S. Arya A. Valluri |
| author_sort | V. Arya |
| collection | DOAJ |
| description | A 72-year-old female and a 57-year-old male with chronic hepatitis C were treated with a combination therapy of pegylated interferon (PEG-IFN)-α 2a (180 µg s.c. once a week) and ribavirin (1,000 mg orally daily). This resulted in the destruction of melanocytes at the injection site in both patients. In the male patient, the depigmentation progressed to the surrounding skin area. The dermatologist concurred with vitiligo as the diagnosis in both patients. Injection and surrounding site vitiligo associated with PEG-IFN-α 2b treatment for hepatitis C was noticed in previous case studies. For the first time, the case reports below highlight the same immunological adverse event secondary to PEG IFN-α 2a/ribavirin combination therapy and explain, in part, the complex interaction between host immune response and viral genotype. In addition, we systematically review drug-induced vitiligo and autoimmune diseases associated with the depigmentation disorder. |
| first_indexed | 2024-12-11T17:00:45Z |
| format | Article |
| id | doaj.art-797cc9b647d44dfaa6d4bc9a47a03b55 |
| institution | Directory Open Access Journal |
| issn | 1662-6567 |
| language | English |
| last_indexed | 2024-12-11T17:00:45Z |
| publishDate | 2010-08-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Dermatology |
| spelling | doaj.art-797cc9b647d44dfaa6d4bc9a47a03b552022-12-22T00:57:49ZengKarger PublishersCase Reports in Dermatology1662-65672010-08-012215616410.1159/000320207320207Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature ReviewV. AryaM. BansalL. GirardS. AryaA. ValluriA 72-year-old female and a 57-year-old male with chronic hepatitis C were treated with a combination therapy of pegylated interferon (PEG-IFN)-α 2a (180 µg s.c. once a week) and ribavirin (1,000 mg orally daily). This resulted in the destruction of melanocytes at the injection site in both patients. In the male patient, the depigmentation progressed to the surrounding skin area. The dermatologist concurred with vitiligo as the diagnosis in both patients. Injection and surrounding site vitiligo associated with PEG-IFN-α 2b treatment for hepatitis C was noticed in previous case studies. For the first time, the case reports below highlight the same immunological adverse event secondary to PEG IFN-α 2a/ribavirin combination therapy and explain, in part, the complex interaction between host immune response and viral genotype. In addition, we systematically review drug-induced vitiligo and autoimmune diseases associated with the depigmentation disorder.http://www.karger.com/Article/FullText/320207VitiligoInjection sitePEG-IFN-α 2aChronic hepatitis C |
| spellingShingle | V. Arya M. Bansal L. Girard S. Arya A. Valluri Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review Case Reports in Dermatology Vitiligo Injection site PEG-IFN-α 2a Chronic hepatitis C |
| title | Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review |
| title_full | Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review |
| title_fullStr | Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review |
| title_full_unstemmed | Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review |
| title_short | Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review |
| title_sort | vitiligo at injection site of peg ifn α 2a in two patients with chronic hepatitis c case report and literature review |
| topic | Vitiligo Injection site PEG-IFN-α 2a Chronic hepatitis C |
| url | http://www.karger.com/Article/FullText/320207 |
| work_keys_str_mv | AT varya vitiligoatinjectionsiteofpegifna2aintwopatientswithchronichepatitisccasereportandliteraturereview AT mbansal vitiligoatinjectionsiteofpegifna2aintwopatientswithchronichepatitisccasereportandliteraturereview AT lgirard vitiligoatinjectionsiteofpegifna2aintwopatientswithchronichepatitisccasereportandliteraturereview AT sarya vitiligoatinjectionsiteofpegifna2aintwopatientswithchronichepatitisccasereportandliteraturereview AT avalluri vitiligoatinjectionsiteofpegifna2aintwopatientswithchronichepatitisccasereportandliteraturereview |